pharmaceuticals

health care

Merrill Lynch Top Healthcare Stock Picks for 2015

Merrill Lynch released its report looking forward to 2015 and which stocks it believes will outperform in the healthcare sector. In 2014, many of these same companies had very strong ...
Read Full Story »
fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
Pfizer logo

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, Celebrex now has a generic competitor in America. The drug company Actavis PLC (NYSE: ACT) announced on Wednesday that it ...
Read Full Story »
IPO

Bellicum Sets Pricing Terms for IPO

Bellicum Pharmaceuticals filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The price for the offering was set between $15 ...
Read Full Story »
biotech

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck & Co. Inc.'s (NYSE: MRK) big jump into the antibiotic space with the purchase of Cubist Pharmaceuticals Inc. (NASDAQ: CBST), sporting a 35% premium for shareholders, already has many ...
Read Full Story »
Pills

Merck, Cubist Agree to $9.5 Billion Acquisition

Drug giant Merck & Co. (NYSE: MRK) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST) have signed a definitive merger agreement under which Merck will acquire Cubist for $102 a share, or, ...
Read Full Story »
DNA

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma Inc. (NASDAQ: ARRY) announced Wednesday after the market close that it had reached a definitive agreement with Novartis A.G. (NYSE: NVS) to regain full worldwide rights to cancer ...
Read Full Story »
Pills

Are Avanir Shareholders Getting Enough in the Buyout?

Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) announced that it has entered into a definitive agreement with Japan’s Otsuka Pharmaceutical for a $17.00 per share buyout. Monday’s closing price was $15.00. After ...
Read Full Story »
Ebola Virus

Big News for Ebola Stocks

Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks. NewLink Genetics Corp. (NASDAQ: ...
Read Full Story »
153576724

Is Orexigen Really Worth Over 50% More?

Merrill Lynch has released an analyst report that sees more than 50% upside for Orexigen Therapeutics Inc. (NASDAQ: OREX). The top analyst on the call was Steve Byrne, and the general ...
Read Full Story »
Botox injection

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Botox maker Allergan Inc. (NYSE: AGN), which has fended off offers up to about $173 per share from Valeant Pharmaceuticals International Inc. (NYSE: VRX), announced Monday morning that it has ...
Read Full Story »
DNA

Juno Therapeutics Files for IPO

Juno Therapeutics Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given in the filing, but it is valued ...
Read Full Story »
biotech

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

One sad trend that has exploded in the new millennium has been the increase in hepatitis C cases in the Unites States and around the world. One startling fact is ...
Read Full Story »
Sad lonely pensive old senior woman

Inotek Pharma Files for IPO

Inotek Pharmaceuticals Corp. has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but ...
Read Full Story »
fda_logo

Is Geron Back From the Dead?

The U.S. Food and Drug Administration (FDA) gave Geron Corp. (NASDAQ: GERN) some good news Monday morning when it removed the clinical hold on the company’s investigational new drug application ...
Read Full Story »